Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the TRIUMPH Trial

NCT00112281 is registered in ClinicalTrials.gov with Arginox Pharmaceuticals as lead sponsor.

NCT NCT00112281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the TRIUMPH Trial
Lead sponsor
Arginox Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2005
Completion date
January 31, 2007
Enrollment
658
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

shock, cardiogenic